Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event Transcript

Operator

Good day, and thanks for standing by. Welcome to the Agios Prescribed drugs European Hematology Affiliation 2026 Investor Webcast and Convention Name.

[Operator Instructions] Please be suggested that immediately’s name is being recorded. I’d now like at hand it over to our first speaker, Morgan Sanford, Head of Investor Relations at Agios. Please go forward.

Morgan Sanford
Vice President of Investor Relations

Thanks, operator. Good morning and good afternoon, everybody, and thanks for becoming a member of us. We’re happy to host immediately’s webcast along with the 2026 EHA Congress, the place we’re presenting a broad set of knowledge throughout our portfolio. You possibly can entry the slides for immediately’s presentation on the Buyers part of our web site.

Please notice that we’ll be making forward-looking statements throughout this presentation. Precise outcomes could differ materially on account of dangers and uncertainties described in our SEC filings.

Becoming a member of me immediately are Brian Goff, Chief Govt Officer; Dr. Sarah Gheuens, Chief Medical Officer and Head of R&D; and Tsveta Milanova, Chief Business Officer. We will even be joined for Q&A by our taking part key opinion